Chen X, Wei X, Yao P, Liu Y, et al. The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study. Clin Breast Cancer 2024 Mar 8:S1526-8209(24)00028.
PMID: 38670862